Originally posted by NextGenSeq
View Post
Seqanswers Leaderboard Ad
Collapse
Announcement
Collapse
No announcement yet.
X
-
Originally posted by Heisman View PostI think your main problem is that you sent your stuff to other labs without publishing it. I'm still not clear why you couldn't just test your products yourself and just publish it. If you send magical formulas to other labs without publishing, it doesn't surprise me that some aspiring scientist may try to claim it as their own in some capacity (or alter it a bit and then claim it as their own).
As for the law aspects; this is a great forum for technology but how many of us are really capable of discussing the law at a high level? Very few, if any, I would guess (certainly not me).
As for your comments on the legal aspect, I wasn't trying to focus too much on the high-level legal aspects (though that would have also been fine to talk about). I was just curious what other people on this forum felt about that case, and more importantly, about how gene patenting and the lack of understanding in our gov't regarding technology (in this case, sequencing) will slow us down in our efforts to help people who are sick. But I get what you mean...sometimes I feel that you do need a law degree to understand even a simple case.
Comment
-
Originally posted by austinso View PostMyriad is a co-licenser with the Hospital for Sick Children's in Toronto for the BRCA1/BRCA2 patents:
As far as I'm concerned, Myriad is just trying to scare people. In the end, defensible IP resides in the assay method to detect the mutation, and not the mutation itself.
I think that is kinda what happened the first time. But then someone challenged them and it went all the way.
What I don't want to happen is that Myriad finds a way to still be able to patent those genes when they are almost done with their patent to begin with. Because if they were able to protect their ability to patent genes then other companies and sleazy start-ups will try to do the same with new genes or regions of the genome.
Basically, this is the real issue (to me, at least): if you spend time and money to determine that a set of genes are definitively related to a disease (or whatever) then should you be able to make money off of that discovery? And should the legal system keep other companies from trying to provide that data to people who could benefit health-wise from it?
I think it is a tough set of questions. Because I feel that capitalism is the best way to move forward. But I also feel that our genome is our's. And if I can sequence my entire genome, then find out (in some way...through the grapevine or the internet...or from wherever) that such-and-such gene could cause cancer for me then I shouldn't be sued for looking at my genome to see if I have it.
If we rule that,regardless, nothing in your personal genome can be patented then will it slow down the pace of research? Is it just the price we are gonna have to pay right now to get the entire genome thoroughly understood? Maybe it is worth it for some people to die now so that WAY more can live in the future?
Comment
Latest Articles
Collapse
-
by seqadmin
The field of epigenetics has traditionally concentrated more on DNA and how changes like methylation and phosphorylation of histones impact gene expression and regulation. However, our increased understanding of RNA modifications and their importance in cellular processes has led to a rise in epitranscriptomics research. “Epitranscriptomics brings together the concepts of epigenetics and gene expression,” explained Adrien Leger, PhD, Principal Research Scientist...-
Channel: Articles
04-22-2024, 07:01 AM -
-
by seqadmin
Proteins are often described as the workhorses of the cell, and identifying their sequences is key to understanding their role in biological processes and disease. Currently, the most common technique used to determine protein sequences is mass spectrometry. While still a valuable tool, mass spectrometry faces several limitations and requires a highly experienced scientist familiar with the equipment to operate it. Additionally, other proteomic methods, like affinity assays, are constrained...-
Channel: Articles
04-04-2024, 04:25 PM -
ad_right_rmr
Collapse
News
Collapse
Topics | Statistics | Last Post | ||
---|---|---|---|---|
Started by seqadmin, 05-02-2024, 08:06 AM
|
0 responses
16 views
0 likes
|
Last Post
by seqadmin
05-02-2024, 08:06 AM
|
||
Started by seqadmin, 04-30-2024, 12:17 PM
|
0 responses
20 views
0 likes
|
Last Post
by seqadmin
04-30-2024, 12:17 PM
|
||
Started by seqadmin, 04-29-2024, 10:49 AM
|
0 responses
25 views
0 likes
|
Last Post
by seqadmin
04-29-2024, 10:49 AM
|
||
Started by seqadmin, 04-25-2024, 11:49 AM
|
0 responses
28 views
0 likes
|
Last Post
by seqadmin
04-25-2024, 11:49 AM
|
Comment